BioCentury | Jan 27, 2017
Clinical News

Zybrestat: Final Ph II Study OX4218 data

Final data from the open-label, U.S. Phase II Study OX4218 in 18 patients with well-differentiated, low-to-intermediate-grade, unresectable, recurrent or metastatic PNETs or GI-NETs showed that 60 mg/m 2 IV Zybrestat on days 1, 8 and...
BioCentury | Sep 29, 2014
Clinical News

Fosbretabulin: Phase II started

OxiGene began an open-label, U.S. Phase II trial to evaluate 60 mg/m 2 IV Zybrestat given on days 1, 8 and 15 of a 3-week cycle for up to 3 cycles or until progression or...
BioCentury | Oct 21, 2013
Clinical News

TKM-PLK1: Additional Phase I data

Additional data from an open-label, dose-escalation, U.S. Phase I trial showed that 6 of 15 evaluable patients receiving IV TKM-PLK1 at doses of >=0.6 mg/kg showed a clinical benefit. There were 3 cases of stable...
BioCentury | Sep 13, 2012
Distillery Therapeutics

Indication: Neurology

...and contact information Neurology Parkinson's disease (PD); amyotrophic lateral sclerosis (ALS) Amyloid precursor protein (APP); chromogranin B (CHGB)...
...models for ALS pretreated with heavy water (2H2O), rates of appearance and disappearance of 2H-labeled Chgb...
...models of PD and in patients with PD, rates of appearance and disappearance of 2H-labeled CHGB...
BioCentury | Sep 13, 2012
Targets & Mechanisms

This is (a diagnostic) spinal tap

...known to rely on axonal transport: soluble amyloid precursor protein ( APP ), chromogranin B ( CHGB...
...healthy mice receiving intracerebroventricular infusions of nocodazole-a microtubule-destabilizing agent that disrupts axonal transport-the rates for Chgb...
...found that in PD mouse models and patients, the rates for three of the proteins-SNCA, CHGB...
BioCentury | Mar 22, 2010
Clinical News

BIM 23A760: Phase II started

Ipsen began an open-label, dose-escalation, international Phase II trial of subcutaneous BIM 23A760 in about 100 patients. Ipsen Group (Euronext:IPN), Paris, France Product: BIM 23A760 Business: Cancer Molecular target: Prolactin (PRL) ; Growth hormone receptor...
BioCentury | Jul 13, 2009
Clinical News

LX1032: Phase II started

Lexicon began a double-blind, placebo-controlled, dose-escalation, U.S. Phase II trial to evaluate up to 4 dose levels of oral LX1032 in about 28 patients for 4 weeks. LX1032 has Fast Track designation in the U.S....
BioCentury | Jul 6, 2009
Clinical News

Afinitor everolimus: Additional Phase II data

Additional data from the open-label, international Phase II RADIANT-1 trial in 160 patients showed that Afinitor everolimus plus Sandostatin LAR decreased tumor size in 84% of patients compared with 60% of those receiving Afinitor alone....
BioCentury | Mar 16, 2009
Clinical News

LX1032: Phase II start

This quarter, Lexicon will begin a double-blind, placebo-controlled, U.S. Phase II trial to evaluate oral LX1032 in about 28 patients. Lexicon licensed LX1032 to Symphony Icon in 2007 (see BioCentury, June 25, 2007). Lexicon Pharmaceuticals...
BioCentury | Sep 22, 2008
Clinical News

Everolimus: Phase II data

In the open-label, international Phase II RADIANT-1 trial in 160 patients with advanced pancreatic NET, the objective response rate was 8% with RAD001 monotherapy and 4% with RAD001 plus Sandostatin LAR. All confirmed responses were...
Items per page:
1 - 10 of 11